Abstract
Hyperalphalipoproteinemia, as observed in patients who are either homozygous or heterozygous for cholesteryl ester transfer protein (CETP) deficiency, has been shown to be associated with striking changes in apolipoprotein size distribution, namely, of high-density lipoprotein (HDL) and HDL-like particles. We compared the effect of varying degrees of CETP activity on the HDL apolipoprotein profile in Caucasian CETP-deficient subjects and following pharmacological decrease in CETP activity, using Size Exclusion Chromatography followed by Reverse Phase Protein Array (SEC RPA). The main HDL-associated apolipoproteins (Apo), i.e. ApoA-I, ApoA-II, ApoC-I, and ApoC-III, co-eluted with the HDL peak. The presence of a HDL-like peak migrating between the ApoB-LDL and ApoA-I-HDL was identified in a Caucasian patient with homozygosity for a point mutation in exon 2 of the CETP gene (c.109 C > T) resulting in a premature termination codon (R37X) and complete CETP deficiency. This HDL-like peak was not observed either in healthy volunteers treated with the CETP modulator dalcetrapib, patients heterozygous for the same mutation, or in patients heterozygous with G165X mutations. SEC RPA offers the possibility to investigate the distribution of a large number of apolipoproteins simultaneously under non-denaturing separation in normal and dyslipidemic subjects. This is only limited by the availability of antibodies against specific apolipoproteins to be investigated.
Keywords: Cholesteryl ester transfer protein, dalcetrapib, high-density lipoprotein, reverse phase protein array, scavenger receptor class B1, size exclusion chromatography, torcetrapib, apolipoprotein, hyperalphalipoproteinemia, ELISA
Current Vascular Pharmacology
Title:Lipid and Apoprotein Composition of HDL in Partial or Complete CETP Deficiency
Volume: 10 Issue: 4
Author(s): Eric J. Niesor, Elisabeth von der Mark, Laura Calabresi, Maurizio Averna, Angelo B. Cefalu, Patrizia Tarugi, Peter Nilsson and Gregor Dernick
Affiliation:
Keywords: Cholesteryl ester transfer protein, dalcetrapib, high-density lipoprotein, reverse phase protein array, scavenger receptor class B1, size exclusion chromatography, torcetrapib, apolipoprotein, hyperalphalipoproteinemia, ELISA
Abstract: Hyperalphalipoproteinemia, as observed in patients who are either homozygous or heterozygous for cholesteryl ester transfer protein (CETP) deficiency, has been shown to be associated with striking changes in apolipoprotein size distribution, namely, of high-density lipoprotein (HDL) and HDL-like particles. We compared the effect of varying degrees of CETP activity on the HDL apolipoprotein profile in Caucasian CETP-deficient subjects and following pharmacological decrease in CETP activity, using Size Exclusion Chromatography followed by Reverse Phase Protein Array (SEC RPA). The main HDL-associated apolipoproteins (Apo), i.e. ApoA-I, ApoA-II, ApoC-I, and ApoC-III, co-eluted with the HDL peak. The presence of a HDL-like peak migrating between the ApoB-LDL and ApoA-I-HDL was identified in a Caucasian patient with homozygosity for a point mutation in exon 2 of the CETP gene (c.109 C > T) resulting in a premature termination codon (R37X) and complete CETP deficiency. This HDL-like peak was not observed either in healthy volunteers treated with the CETP modulator dalcetrapib, patients heterozygous for the same mutation, or in patients heterozygous with G165X mutations. SEC RPA offers the possibility to investigate the distribution of a large number of apolipoproteins simultaneously under non-denaturing separation in normal and dyslipidemic subjects. This is only limited by the availability of antibodies against specific apolipoproteins to be investigated.
Export Options
About this article
Cite this article as:
J. Niesor Eric, von der Mark Elisabeth, Calabresi Laura, Averna Maurizio, B. Cefalu Angelo, Tarugi Patrizia, Nilsson Peter and Dernick Gregor, Lipid and Apoprotein Composition of HDL in Partial or Complete CETP Deficiency, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812683
DOI https://dx.doi.org/10.2174/157016112800812683 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents in Diagnosis of Preeclampsia
Recent Patents on Biomarkers Editorial [Hot Topic:Lipid Lowering Agents (Guest Editor: John W. Clader)]
Current Topics in Medicinal Chemistry MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome
Current Vascular Pharmacology Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Novel Concept in the Mechanism of Injury and Protection of Gastric Mucosa: Role of Renin-Angiotensin System and Active Metabolites of Angiotensin
Current Medicinal Chemistry 6-(Arylaminomethyl) Isoquinolines as Enzyme Inhibitors and Their Preparation: A Patent Highlight of Factor XIIa Inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry Periodontitis and Periodontal Disease - Innovative Strategies for Reversing the Chronic Infectious and Inflammatory Condition by Natural Products
Current Pharmaceutical Design Contribution of Ultrasonography of Hands and Wrists in Early Rheumatoid Arthritis
Current Rheumatology Reviews Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Current Vascular Pharmacology Right Heart Catheterization Through Persistent Left Superior Vena Cava, an Extremely Rare Procedure and Review of Current Literature
Current Cardiology Reviews Aquaporins as Targets for Drug Discovery
Current Pharmaceutical Design Pharmacological Neuroprotection in Cardiac Surgery: Effectiveness of Pharmacologic-Preconditioning with Erythromycin
Current Vascular Pharmacology Human Myoblast Genome Therapies and Devices in Regenerative Medicine
Recent Patents on Regenerative Medicine Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry COX-Inhibiting Nitric Oxide Donors (CINODs): Potential Benefits on Cardiovascular and Renal Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Thiazide Diuretics: 50 Years and Beyond
Current Hypertension Reviews Renal Endothelial Dysfunction in Acute Kidney Ischemia Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Inhaled Nitric Oxide in Preterm Neonates with Refractory Hypoxemia Associated to Oligohydramnios
Current Drug Discovery Technologies